BMY vs MDLN
BMY: A diversified biopharmaceutical company leveraging immunotherapy, cell therapies, and small-molecule platforms to address cancer, autoimmune disease, and specialty care. MDLN: Medline is a global healthcare products and services distributor supplying hospitals, clinics, and other healthcare settings with medical supplies, equipment, and solutions.
Side-by-side fundamentals
| Metric | BMY | MDLN | Edge |
|---|---|---|---|
| Price as of 2026-07-15 close | $58.72 | $39.44 | |
| Market cap as of 2026-07-16 | $119.5B | $51.8B | |
| P/E as of 2026-07-16 | 19.99 | 53.64 | BMY lower |
| PEG as of 2026-07-16 | -4.29 | 11.46 | BMY lower |
| Net margin as of 2026-07-16 | +12.3% | +3.3% | BMY higher |
| Gross margin as of 2026-07-16 | +53.7% | +25.9% | BMY higher |
| Operating margin as of 2026-07-16 | +17.1% | +7.1% | BMY higher |
| ROE as of 2026-07-16 | +41.6% | +6.9% | BMY higher |
| ROA as of 2026-07-16 | +8.7% | +2.6% | BMY higher |
| Debt / equity as of 2026-07-16 | 2.22 | 1.12 | MDLN lower |
| Revenue growth (YoY) as of 2026-07-16 | +1.8% | +10.7% | MDLN higher |
| Revenue CAGR (3y) SEC XBRL | +1.4% | +10.6% | MDLN higher |
| Dividend yield as of 2026-07-16 | +4.4% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-07-16 | 0.24 | 1.12 | |
| 1-year return as of 2026-07-15 close | +20.3% | -8.0% | BMY higher |
Fundamentals: Finnhub, as of 2026-07-16. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-15.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.